"today's announcement reduces the overall risk profile"
Given that this announcement relates to new conditions, I'm pretty sure it has no direct impact on the risks or expectations around the existing trials. We will require a whole nother set of trials to validate these new results.
It does alter the risk/reward balance a little in favour of reward because it offers the prospect of additional detectable conditions and therefore a broader or stronger revenue base for the eventual product.
RAP Price at posting:
9.4¢ Sentiment: Hold Disclosure: Held
